Thyroid Dysfunction and Nivolumab Reponse in NSCLC

Inclusion Criteria: * patients at least 18 years old and had histologically confirmed locally advanced stage (IIIB) or metastatic (IV) non-small cell lung cancer with disease progression; * treated with Nivolumab® as second or more therapeutic line * in the oncologic department university hospital of Brest * during the inclusion period between July 20, 2015 to June 30, 2018. Exclusion Criteria: * patients whose primary tumor was not from bronchopulmonary origin * patients with a history of total thyroidectomy and/or having previously treated with levothyroxine and/or having a thyroid dysfunction previously to the introduction of Nivolumab® * patients not having any thyroid monitoring during Nivolumab® treatment, and those for which data were missing * patients who expressed their opposition to participate in the study